Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01262092 · ClinicalTrials.gov registry record · Phase 2
Effects of Gabapentin Versus Placebo on Buprenorphine Detoxification of Opioid-dependent Individuals
A Phase 2 study, sponsored by University of Arkansas.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT01262092 is a Phase 2 study that has completed, run by University of Arkansas. The registered enrollment target is 30 participants.
The verdict
NCT01262092, a Phase 2 study, has completed, sponsored by University of Arkansas.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
This study involves inducting treatment seeking opioid dependent participants onto buprenorphine. Once the participant reaches a stable dose they will receive either placebo or gabapentin to determine if gabapentin helps ease withdrawal symptoms while the participant undergoes a 10-day buprenorphine detoxification.
Interventions
- DRUG Buprenorphine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2010-10 |
| Est. Completion | 2012-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01262092
The ClinicalTrials.gov registry entry for NCT01262092 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Arkansas, which has 318 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Buprenorphine is the first listed.
NCT01262092 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01262092 about?
NCT01262092 is a clinical study titled "Effects of Gabapentin Versus Placebo on Buprenorphine Detoxification of Opioid-dependent Individuals". This study involves inducting treatment seeking opioid dependent participants onto buprenorphine. Once the participant reaches a stable dose they will receive either placebo or gabapentin to determine if gabapentin helps ease withdrawal symptoms while the participant undergoes a 10-day buprenorphine...
What is the current status of trial NCT01262092?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2010-10. Estimated completion is 2012-01.
What interventions are being tested in trial NCT01262092?
The interventions under investigation include: Buprenorphine (DRUG).
Who is sponsoring clinical trial NCT01262092?
This trial is sponsored by University of Arkansas, which has 318 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.